← Back to patent-cliff list
Belvarafenib
Tier C — Watch / tradeBelvarafenib
Hanmi Pharmaceutical Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：B-raf V600E, B-raf, C-Raf
Indications (approved)：脑癌, Melanoma, Solid tumour
Regional status
US
Phase II
2021-01-18
EU
Phase II
2021-01-18
China
Phase II
2021-01-18
Japan
Phase II
2021-01-18
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Belvarafenib?
Approved indications include: 脑癌, Melanoma, Solid tumour.
When does the Belvarafenib patent expire?
No public expiry year is available for Belvarafenib yet; this page updates once verified.
How do I get a quote for Belvarafenib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06